ezetimibe has been researched along with Insulin Resistance in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 29 (78.38) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Papachristou, S; Papanas, N; Popovic, DS; Stokic, E | 1 |
| Adachi, H; Hakoshima, M; Katsuyama, H; Yanai, H | 1 |
| Abe, M; Fukuda, N; Haketa, A; Hatanaka, Y; Kobayashi, H; Nakamura, Y; Soma, M; Tanaka, S; Tsunemi, A; Ueno, T | 1 |
| Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T | 1 |
| Ganesan, S; Ito, MK | 1 |
| Sano, M | 1 |
| Abate, N; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M; Sallam, HS | 1 |
| Krysiak, R; Okopien, B; Zmuda, W | 1 |
| Guo, Y; Liang, Y; Liu, S; Ren, Q; Wang, X; Wu, T | 1 |
| Cui, CJ; Li, JJ; Li, S | 1 |
| Adachi, H; Bekki, H; Honma, T; Nakano, H; Nakata, M; Nohara, M; Yamamoto, K; Yoshiyama, H | 1 |
| Han, SH; Hayashi, T; Kim, EY; Koh, KK; Lee, Y; Oh, PC; Park, YM; Sakuma, I; Shin, EK | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Couture, P; Drouin-Chartier, JP; Lamarche, B; Lemelin, V; Lépine, MC; Tremblay, AJ | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Duarte, F; Ginsberg, HN; Khavandi, M; Reyes-Soffer, G | 1 |
| Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE | 1 |
| Ishii, H; Kawakami, A; Nomura, M; Yoshida, M | 1 |
| Barrett, PH; Chan, DC; Gan, SK; Ooi, EM; Watts, GF | 1 |
| Batista, MC; Ferreira, SR; Kater, AL | 1 |
| Ahmed, MH | 1 |
| Machann, J; Pfeiffer, AF; Rudovich, NN; Weickert, MO | 1 |
| Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S | 1 |
| Ahmed, MH; Byrne, CD | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Aburatani, H; Aoki, K; Iwasaki, T; Kadowaki, T; Kubota, N; Mori, S; Muraoka, T; Nakamura, A; Shinoda, K; Terauchi, Y; Tokuyama, K | 1 |
| Elisaf, M; Kei, AA; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H; Moutzouri, E | 1 |
| Morinaga, Y; Nakazato, M; Shiiya, T; Tamaki, N; Ueno, H | 1 |
| Elisaf, MS; Florentin, M; Liamis, G; Liberopoulos, EN; Moutzouri, E | 1 |
| Chait, A; Ding, Y; Goodspeed, L; Han, CY; Kim, J; O'Brien, KD; Subramanian, S; Teresa, AS; Umemoto, T; Wang, S | 1 |
| Gu, P; Jiang, S; Lu, B; Shao, J; Wang, J; Zhong, Y | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Krone, W; Müller-Wieland, D | 1 |
| González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E; Ramos-Zavala, MG | 1 |
| Ahmed, MH; Osman, MM; Saad, RA | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
8 review(s) available for ezetimibe and Insulin Resistance
| Article | Year |
|---|---|
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipoproteins; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2022 |
[An inhibitor of intestinal cholesterol transporter].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hypercholesterolemia; Insulin Resistance; Intestinal Absorption | 2013 |
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Insulin Resistance; Lipids; Lipoproteins; Metabolic Syndrome; Metformin; Niacin; Thiazolidinediones | 2014 |
PCSK9 and its modulation.
Topics: Age Factors; Atherosclerosis; Azetidines; Cholesterol; Circadian Rhythm; Diet; Drugs, Chinese Herbal; Exercise; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Kidney Diseases; Liver Regeneration; Molecular Targeted Therapy; Proprotein Convertase 9; Proprotein Convertases; Risk Factors; Serine Endopeptidases | 2015 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Life Style; Lipoproteins; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2017 |
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biological Transport; Cholesterol; Chylomicrons; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Intestines; Metabolic Syndrome; Rats | 2010 |
[Hyperlipidemia: therapeutic principles in clinical practice].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss | 2003 |
9 trial(s) available for ezetimibe and Insulin Resistance
| Article | Year |
|---|---|
Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.
Topics: Atherosclerosis; Biomarkers; Drug Therapy, Combination; Ezetimibe; Female; Hepatocyte Growth Factor; Humans; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Obesity | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind Method; Duodenum; Dyslipidemias; Endoscopy, Digestive System; Ezetimibe; Gene Expression; Humans; Hydroxymethylglutaryl CoA Reductases; Insulin; Insulin Resistance; Male; Middle Aged; Proprotein Convertase 9; Real-Time Polymerase Chain Reaction; Receptors, LDL; RNA, Messenger; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2016 |
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
Topics: Adipokines; Aged; alpha-2-HS-Glycoprotein; Anticholesteremic Agents; Apolipoprotein B-100; Azetidines; Biomarkers; Blood Proteins; Body Composition; C-Reactive Protein; Combined Modality Therapy; Diet, Reducing; Ezetimibe; Fatty Liver; Humans; Insulin Resistance; Liver; Middle Aged; Obesity; Patient Compliance; Triglycerides; Weight Loss | 2010 |
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
Topics: Adolescent; Adult; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Biomarkers; Blood Coagulation; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Prediabetic State; Simvastatin; Young Adult | 2010 |
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
Topics: Aged; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fasting; Female; Fluorobenzenes; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Medication Adherence; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Middle Aged; Prospective Studies; Uric Acid | 2013 |
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Azetidines; Blood Glucose; Blood Pressure Determination; Body Mass Index; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Ezetimibe; Female; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Obesity; Time Factors; Treatment Outcome | 2006 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
20 other study(ies) available for ezetimibe and Insulin Resistance
| Article | Year |
|---|---|
Ezetimibe and Insulin Resistance.
Topics: Anticholesteremic Agents; Ezetimibe; Humans; Hypercholesterolemia; Insulin Resistance | 2022 |
Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
Topics: Adult; Age of Onset; Bezafibrate; Diabetes Complications; Ezetimibe; Genetic Variation; Heterozygote; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoprotein Lipase; Male | 2019 |
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides | 2019 |
Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Azetidines; Diabetes Mellitus; Drug Interactions; Ezetimibe; Glucose Transporter Type 4; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Simvastatin; Ubiquinone | 2013 |
The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Middle Aged; Polycystic Ovary Syndrome; Simvastatin; Testosterone | 2014 |
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Topics: Acetyl-CoA Carboxylase; Animals; Anticholesteremic Agents; Azetidines; CD36 Antigens; Diet, High-Fat; Ezetimibe; Fatty Acids; Fibrosis; Hyperinsulinism; Insulin Resistance; Lipid Metabolism; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Stearoyl-CoA Desaturase | 2014 |
Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia.
Topics: Adiponectin; Aged; Animals; Anticholesteremic Agents; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Fat Body; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Randomized Controlled Trials as Topic; Rats; Simvastatin; Single-Blind Method | 2015 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides | 2017 |
Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blotting, Western; Cells, Cultured; Cholesterol; DNA Primers; Endoplasmic Reticulum; Ezetimibe; Fatty Liver; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Liver; Male; Membrane Transport Proteins; Pyruvic Acid; Rats; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Superoxides; Triglycerides | 2009 |
Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Clinical Trials as Topic; Diet; Drug Evaluation, Preclinical; Ezetimibe; Fatty Liver; Gallstones; Humans; Insulin Resistance; Intestine, Small | 2010 |
Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance?
Topics: Acarbose; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance | 2010 |
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Fatty Liver; Humans; Inflammation; Insulin Resistance; Liver; Membrane Proteins; Membrane Transport Proteins | 2010 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Topics: Adiposity; Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cells, Cultured; Cholesterol, LDL; Dietary Fats; Ezetimibe; Fatty Liver; Glucose; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2011 |
Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.
Topics: Administration, Oral; Anticholesteremic Agents; Asian People; Atherosclerosis; Azetidines; Biomarkers; Case-Control Studies; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver Diseases; Male; Matrix Metalloproteinase 9; Middle Aged; Prognosis; Prospective Studies; Vascular Cell Adhesion Molecule-1 | 2012 |
Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.
Topics: Adipose Tissue; Animals; Atherosclerosis; Azetidines; Cholesterol; Ezetimibe; Immunohistochemistry; Inflammation; Insulin Resistance; Intestinal Absorption; Intestines; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Real-Time Polymerase Chain Reaction; Receptors, LDL; Weight Gain | 2012 |
Effect of ezetimibe on insulin secretion in db/db diabetic mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Diabetes Complications; Diabetes Mellitus, Type 2; Ezetimibe; Glucose Intolerance; Hypercholesterolemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Kinetics; Male; Mice; Mice, Congenic; Mice, Mutant Strains; Random Allocation; Specific Pathogen-Free Organisms | 2012 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin | 2006 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |